AtriCure, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael H. Carrel
- Full Time Employees
- 1,350
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 7555 Innovation Way Mason OH United States of America 45040
- IPO Date
- Aug 5, 2005
- CIK
- 0001323885
- Website
- atricure.com
- Similar Companies
- Business
- AtriCure, Inc. develops, manufactures, and sells advanced medical devices primarily for the surgical treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Its core product portfolio includes surgical ablation systems such as the Isolator® Synergy™ Access® Clamp, Isolator® Synergy™ Clamps, and the Isolator® Transpolar Pen; the AtriClip® devices for LAA exclusion including models like AtriClip PRO®, AtriClip FLEX™, and their Mini variants; cryoSPHERE® devices and related probes for cryo nerve block therapy targeting pain management; and minimally invasive surgical instruments including the EPi-Ease™ Epicardial Access Device and atrial lift systems. The company also offers hybrid total thoracoscopic therapy for long-standing persistent Afib. Founded in 2000 and headquartered in Mason, Ohio, AtriCure operates globally, targeting cardiac surgeons, electrophysiologists, and hospitals involved in cardiac surgery. Recent major changes include the successful launch of new products like the AtriClip Flex Mini and cryoSPHERE MAX probes, which have driven accelerated growth in appendage and pain management segments. The company achieved significant revenue growth for 2025, projecting revenues between $532 million and $534 million, which represents double-digit percentage increases year over year. AtriCure also advanced development in pulse field ablation (PFA) technology for cardiac surgery and expanded its global manufacturing and R&D facilities in Mason, Ohio. Additionally, the company completed strategic acquisitions earlier, such as that of Estech, enhancing its surgical ablation portfolio with radio-frequency technologies. These developments reinforce AtriCure’s leadership position in surgical Afib treatments, LAA management, and postoperative pain therapies across multiple international markets.
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
A Look at AtriCure Inc (ATRC) After 6.0% Decline -- GF Value $39.32 vs Price $37.76
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
AtriCure Q2 Earnings Call Highlights
AtriCure Reports Second Quarter 2026 Financial Results
AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure to Announce Second Quarter 2026 Financial Results
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
Do Options Traders Know Something About AtriCure Stock We Don't?
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript